Throughout the course of the project we will engage with other projects that are involved in similar studies.
REDDSTAR is an EU funded project which will develop and test stromal cell therapy to treat for diabetes mellitus. The objective is to control blood glucose while also addressing a range of diabetic complications. ADIPOA-2 partners NUI Galway and Pintail also collaborate on REDDSTAR.
ADIPOA-2 partners NUI Glaway and Pintail Limited participate in the FP7-funded project VISICORT. The project will design and initiate an optimised clinical trial strategy of immunomodulatory stromal stem cell therapy in high-risk human corneal transplant recipients.
MERLIN explores exciting new opportunities in stromal cell therapy R&D, while making important contributions to the treatment of currently intractable inflammatory and immune mediated liver diseases. ADIPOA-2 partner Pintail is also involved in MERLIN.
ADIPOA-2 partners NUI Galway and Pintail are collaborators in the Horizon 2020 project NEPHSTROM. The project will carry out a first in man Phase 1b/2a clinical trial of a novel stromal cell therapy for diabetic kidney disease.
The ADIPOA project, which involved a number of the ADIPOA-2 partners, conducted initial research on the use of autologous adipose stem cells to treat osteoarthritis. ADIPOA carried out a Phase 1 clinical trial, which provided essential data for ADIPOA-2.
The goal of VascuBone is to develop a ‘toolbox’ for bone regeneration. The toolbox will include a variation of biocompatible biomaterials and cell types, FDA approved growth factors, material modification technologies, simulation and analytical tools like molecular imaging based in vivo diagnostics which can be combined for the medical need of a specific patient.